Medical Properties Trust Valuation
Is M3P undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of M3P when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: M3P (€5.41) is trading below our estimate of fair value (€7.68)
Significantly Below Fair Value: M3P is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for M3P?
Key metric: As M3P is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is M3P's PS Ratio? | |
|---|---|
| PS Ratio | 3.9x |
| Sales | US$660.17m |
| Market Cap | US$2.59b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 17.5x |
| Enterprise Value/EBITDA | 28.8x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does M3P's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 8.2x | ||
COFB Cofinimmo | 5.4x | -0.1% | €2.1b |
NHI National Health Investors | 10.7x | 13.7% | US$3.5b |
AED Aedifica/SA | 8x | 3.7% | €2.7b |
LTC LTC Properties | 8.9x | -2.4% | US$1.8b |
M3P Medical Properties Trust | 3.9x | 9.1% | €2.6b |
Price-To-Sales vs Peers: M3P is good value based on its Price-To-Sales Ratio (3.9x) compared to the peer average (8.2x).
Price to Sales Ratio vs Industry
How does M3P's PS Ratio compare vs other companies in the Global Health Care REITs Industry?
| 4 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 4 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: M3P is good value based on its Price-To-Sales Ratio (3.9x) compared to the Global Health Care REITs industry average (6.5x).
Price to Sales Ratio vs Fair Ratio
What is M3P's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 3.9x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate M3P's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.